Financial Performance - The company's operating revenue for the first half of 2020 was CNY 237,700,573.43, a decrease of 16.08% compared to CNY 283,262,478.34 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 32,445,032.08, down 14.00% from CNY 37,728,276.36 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 27,979,413.88, a decline of 22.26% compared to CNY 35,992,233.61 last year[19]. - The net cash flow from operating activities was CNY 15,605,134.91, a significant drop of 50.28% from CNY 31,388,822.18 in the same period last year[19]. - Basic earnings per share decreased to CNY 0.38, down 13.64% from CNY 0.44 in the previous year[19]. - Total revenue for the reporting period was ¥237,700,573.43, a decrease of 16.08% compared to ¥283,262,478.34 in the same period last year[63]. - The company reported a net cash flow from operating activities of ¥36,947,804.07, a decrease of 10.9% compared to ¥41,462,492.69 in the same period of 2019[180]. - The company reported a total cash outflow related to other operating activities of CNY 93,877,475.83, compared to CNY 109,215,291.65 in the previous year, reflecting a reduction in operational expenses[179]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,037,204,074.64, an increase of 11.66% from CNY 928,877,916.40 at the end of the previous year[19]. - The total liabilities rose to CNY 338,506,598.52, up from CNY 254,168,436.92, indicating a growth of approximately 33.2%[160]. - Cash and cash equivalents at the end of the reporting period were ¥105,369,837.40, a slight increase from ¥86,599,769.19 in the previous year[69]. - Accounts receivable increased to ¥307,387,153.50, representing 29.64% of total assets, primarily due to the acquisition of Bohua Pharmaceutical[69]. - Inventory increased to ¥72,136,959.80, accounting for 6.95% of total assets, mainly due to the acquisition of Bohua Pharmaceutical[69]. - Total assets increased to CNY 1,037,204,074.64 as of June 30, 2020, up from CNY 928,877,916.40 at the end of 2019, representing an increase of approximately 11.7%[161]. - The company's equity attributable to shareholders increased to CNY 687,016,449.15, compared to CNY 674,709,479.48, reflecting a growth of about 1.8%[161]. Market and Product Development - The company has a total of 74 approved drug products, including 44 varieties listed in the 2019 National Medical Insurance Catalog, with 21 classified as Category A and 23 as Category B[27]. - The main product, Panlong Qipian, is a unique Category A drug composed of 29 herbal ingredients, demonstrating significant therapeutic effects for conditions such as rheumatoid arthritis and osteoarthritis[28]. - The company is focusing on expanding its market presence and product range, particularly in the OTC category, with 37 products included[27]. - The company has developed proprietary products such as Jin Yin Li Dan capsules and Ke Bi Re Ti tablets, targeting specific health issues with unique formulations[29][30]. - The company has established a research institute to strengthen its R&D capabilities and improve product competitiveness[38]. - The company’s product line includes over 100 varieties across nine functional categories, focusing on traditional Chinese medicine and health products[37]. - The company plans to continue its investment and acquisition activities to drive sustained growth in performance[36]. Strategic Initiatives - The company plans to expand its retail team to enhance dual-channel market development for clinical and retail sales[33]. - The company has engaged in share repurchase activities as part of its capital management strategy[127]. - The company has actively participated in social welfare activities, including donations to support education and aid for vulnerable groups[121]. - The company has established a long-term mechanism for poverty alleviation, combining "blood transfusion" and "blood production" support[125]. - The company has invested CNY 6.47 million in the expansion of the acetic acid cotton phenol raw material production line, achieving an 11.15% progress rate[89]. Challenges and Risks - The company is facing substantial macroeconomic risks due to the transition to a high-quality, medium-low speed development phase, which may adversely affect its operating environment[93]. - The pharmaceutical industry is experiencing increased regulatory scrutiny, impacting various operational aspects, including R&D and pricing strategies[94]. - The company is at risk of further price reductions for its drugs due to national policies and market competition, which could affect profitability[94]. - Rising prices of raw materials, particularly traditional Chinese medicine ingredients, pose a risk to industry profits, prompting the company to secure stable supply relationships[95]. - The COVID-19 pandemic initially caused a nearly 30% drop in patient visits to public and private healthcare institutions in Q1 2020, but recovery began in late March as the situation improved[34]. Corporate Governance - The financial report for the first half of 2020 has not been audited[156]. - The company has not faced any major litigation or regulatory penalties during the reporting period[105][106]. - The company has not encountered any issues with the management and use of raised funds, ensuring compliance with regulations[84]. - The company has disclosed its acquisition and share repurchase details on the official website for transparency[130].

Financial Performance - The company's operating revenue for Q1 2020 was ¥81,187,108.55, representing a decrease of 32.64% compared to ¥120,534,391.24 in the same period last year[8] - The net profit attributable to shareholders for Q1 2020 was ¥9,838,934.82, down 17.92% from ¥11,986,886.45 in the previous year[8] - The basic earnings per share for Q1 2020 was ¥0.1138, a decrease of 17.72% from ¥0.1383 in the previous year[8] - Revenue decreased by 32.64% to ¥81.19 million, primarily due to a decline in sales volume impacted by the pandemic[15] - Net profit for Q1 2020 was CNY 9,838,934.82, down from CNY 11,986,886.45 in the same period last year, indicating a decline of approximately 17.9%[43] - The total comprehensive income for the period was CNY 9,838,934.82, compared to CNY 11,986,886.45 in the previous period[47] Cash Flow and Liquidity - The net cash flow from operating activities increased by 120.70% to ¥21,217,100.69, compared to ¥9,613,393.35 in the same period last year[8] - Cash and cash equivalents increased by 59.53% to ¥187.74 million due to bank loans[15] - The cash flow from operating activities generated a net amount of CNY 21,217,100.69, an increase from CNY 9,613,393.35 in the previous year[51] - The company reported a cash and cash equivalents balance of CNY 187,742,655.30 at the end of the period, up from CNY 75,157,539.57 at the end of the previous period[52] - The net increase in cash and cash equivalents was $17.99 million, a significant recovery from a decrease of $13.54 million in the prior period[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥971,406,927.49, an increase of 4.58% from ¥928,877,916.40 at the end of the previous year[8] - The total current liabilities rose to CNY 270,601,857.22 from CNY 234,675,869.15, indicating an increase of approximately 15.3%[35] - The company's total liabilities increased to CNY 293,737,808.12 from CNY 254,168,436.92, marking a rise of about 15.6%[35] - The company's non-current assets totaled CNY 250,384,659.40, up from CNY 237,961,568.08, reflecting an increase of approximately 5.3%[34] - The company's inventory increased to CNY 61,029,678.51 from CNY 57,891,223.09, showing a growth of about 3.7%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,570[11] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] - The company repurchased 269,900 shares, representing 0.31% of total shares, at a maximum price of ¥25.93 per share[17] Operational Changes and Investments - The company received a temporary health permit for producing liquid disinfectants, enhancing market supply of disinfectant products[18] - The company obtained a trademark registration certificate, strengthening brand protection and market competitiveness[18] - Construction in progress rose by 48.09% to ¥32.58 million, driven by investments in production line expansion[15] - The company reported a total of CNY 23,400,000 in entrusted financial management, with CNY 13,400,000 sourced from raised funds and CNY 10,000,000 from self-owned funds[24][25] Cost Management - Total operating costs decreased to CNY 70,973,509.39 from CNY 107,623,969.28, reflecting a cost reduction strategy[42] - Sales expenses decreased by 42.04% to ¥33.73 million, mainly due to reduced revenue from the pandemic[15] - The total operating expenses, including sales and management costs, were CNY 44,554,576.05, compared to CNY 70,864,079.36 in the previous year, indicating a reduction in operational costs[46] - Research and development expenses were CNY 1,265,882.19, down from CNY 1,718,105.72, indicating a decrease of approximately 26.3%[42]

Financial Performance - The company's operating revenue for 2019 was ¥610,636,793.21, representing a 24.76% increase compared to ¥489,447,811.58 in 2018[6]. - The net profit attributable to shareholders for 2019 was ¥71,778,896.72, a 10.97% increase from ¥64,681,884.51 in 2018[6]. - The net profit after deducting non-recurring gains and losses was ¥65,134,853.64, which is a 38.65% increase from ¥46,976,467.38 in 2018[6]. - The net cash flow from operating activities reached ¥67,886,531.13, up 44.91% from ¥46,846,106.88 in 2018[6]. - The total assets at the end of 2019 were ¥928,877,916.40, reflecting a 13.58% increase from ¥817,835,805.47 at the end of 2018[6]. - The net assets attributable to shareholders increased by 10.32% to ¥674,709,479.48 at the end of 2019 from ¥611,597,582.76 at the end of 2018[6]. - The company reported a basic earnings per share of ¥0.83 for 2019, a 10.67% increase from ¥0.75 in 2018[6]. - The company achieved a revenue of ¥610,636,793.21, representing a 24.76% increase compared to the previous year[51]. - The net profit attributable to shareholders was ¥71,778,896.72, reflecting a growth of 10.97% year-over-year[51]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[112]. Dividend Policy - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares to all shareholders, based on a total of 86,670,000 shares[4]. - The company plans to distribute a cash dividend of RMB 1.50 per 10 shares, totaling RMB 13,000,500, which represents 18.11% of the net profit attributable to shareholders for 2019[110]. - The cash dividend policy complies with the company's articles of association and shareholder resolutions, ensuring the protection of minority shareholders' rights[108]. - The company has maintained a consistent cash dividend distribution over the past three years, with the 2018 dividend being RMB 1.00 per 10 shares[109]. Research and Development - The company has established a research institute to enhance its R&D capabilities, focusing on the mechanism and pharmacology of its leading product, Panlong Qipian[36]. - R&D expenses increased by 57.75% compared to the previous year, indicating a strong commitment to innovation[52]. - The company has applied for six invention patents in 2019, including methods for preparing health products and traditional Chinese medicine sprays[54]. - The company is committed to continuous investment in research and development, with plans to enhance its scientific research capabilities and team building[55]. - The company has successfully developed and is preparing to submit applications for two health food products, including Tianma Suanzaoren soft capsules and Wuweizi Lingzhi oral liquid[54]. Market and Product Development - The company has a diverse product line with over 100 varieties across nine functional categories, including its pediatric product, Xiaoer Yanbian Granules, which has seen steady market growth[37]. - The company aims to strengthen its industry position through continuous innovation and investment in R&D, particularly in the health sector[38]. - The company is actively expanding its commercial distribution and retail channels to enhance its market presence and drive revenue growth[38]. - The company has developed and launched several health products, including Panlong Seven toothpaste and Panlong Seven cold compress gel, indicating a trend towards expanding into more fields[41]. - The company has developed Ke Bi Re Ti tablets, which effectively treat skin diseases and fill a market gap for oral medications in this category[29]. Supply Chain and Production - The company has established a stable supply relationship with local farmers in the Qinling area to ensure the quality and supply of traditional Chinese medicinal materials[43]. - The company employs a "production based on demand" procurement model, maintaining a 20-35 day inventory for raw materials[30]. - The company’s production is organized based on orders and inventory, ensuring efficient resource management and compliance with GMP standards[31]. - The company has built a comprehensive supply chain, including a 5,000-acre base for rare medicinal materials to ensure raw material supply[51]. Strategic Initiatives - The company plans to expand its market share by leveraging its brand advantages and enhancing the promotion of its core products[36]. - The company is focusing on the development of traditional Chinese medicine, supported by various national policies aimed at promoting the industry[98]. - The company plans to implement a "Four-Five Plan" to enhance quality management and product innovation, aiming for steady growth and compliance[100]. - The company is committed to improving quality management to mitigate risks associated with product safety and regulatory compliance[103]. Social Responsibility - The company invested ¥1,223.1 million in poverty alleviation projects, benefiting 7,129 impoverished individuals through the establishment of medicinal herb planting bases[57]. - The company has actively engaged in public welfare initiatives, including donations to social organizations for poverty alleviation[171]. - The company has been recognized with numerous awards for its commitment to social responsibility and poverty alleviation efforts[161]. Corporate Governance - The company has committed to avoiding and minimizing related party transactions to protect the interests of shareholders[132]. - The company has established conditions under which it can terminate the stock repurchase plan if the stock price exceeds the audited net asset value per share for three consecutive trading days[118]. - The company has confirmed that it will not participate in any competitive business activities during its period as a major shareholder of the issuer[127]. - The company has established a profit distribution policy that prioritizes cash dividends over stock dividends, enhancing the protection of minority investors' interests[134].

第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)吴继文声明：保证季度报告中财务报表的真实、准确、完整。 陕西盘龙药业集团股份有限公司 2019 年第三季度报告全文 陕西盘龙药业集团股份有限公司 2019 年第三季度报告 2019 年 10 月 1 陕西盘龙药业集团股份有限公司 2019 年第三季度报告全文 2 陕西盘龙药业集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 879,405,458.89 | | 817,835,805.47 | 7.53% | | 归属于上市公司股东的净资产 | 660,984, ...

陕西盘龙药业集团股份有限公司 2019 年半年度报告全文 陕西盘龙药业集团股份有限公司 2019 年半年度报告 2019 年 08 月 1 陕西盘龙药业集团股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)吴继文声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，业绩预测等均不构成公司对广大投资 者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并应当理解 计划、预测与承诺之间的差异，敬请投资者注意投资风险，理性投资。 风险因素详见第四节第十部分"公司面临的风险和应对措施"，请投资者 注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 2019 | 年半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 1 | | 第二节 | ...

Financial Performance - The company's operating revenue for Q1 2019 was ¥120,534,391.24, representing a 27.89% increase compared to ¥94,246,673.75 in the same period last year[8] - Net profit attributable to shareholders was ¥11,986,886.45, up 24.69% from ¥9,613,067.73 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached ¥10,489,539.40, reflecting a 27.67% increase from ¥8,215,885.68 in the previous year[8] - Basic earnings per share increased to ¥0.1383, a rise of 24.71% from ¥0.1109[8] - Total operating revenue for Q1 2019 reached ¥120,534,391.24, an increase of 28% compared to ¥94,246,673.75 in the same period last year[35] - Net profit for Q1 2019 was ¥11,986,886.45, representing a 25% increase from ¥9,613,067.73 in Q1 2018[36] - The total profit for the current period was ¥14,267,042.96, compared to ¥10,772,342.82 in the previous period, marking an increase of around 32.7%[40] Cash Flow - The net cash flow from operating activities surged by 160.00%, amounting to ¥9,613,393.35 compared to ¥3,697,480.38 in the same period last year[8] - Net cash flow from operating activities increased by 160.00% to ¥9,613,393.35, up from ¥3,697,480.38, mainly due to the growth in operating revenue[16] - The company reported cash inflows from operating activities totaling ¥148,079,261.81, compared to ¥101,777,615.07 in the previous period, which is an increase of about 45.4%[44] - The cash outflows from operating activities were ¥138,465,868.46, up from ¥98,080,134.69, indicating an increase of approximately 40.9%[44] - The company experienced a net cash outflow from investing activities of ¥19,579,010.68, compared to a larger outflow of ¥235,730,442.85 in the previous period[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥835,336,416.14, a 2.14% increase from ¥817,835,805.47 at the end of the previous year[8] - The company's total liabilities increased slightly to ¥211,751,946.93 from ¥206,238,222.71, reflecting ongoing operational commitments[27] - The total assets of the company as of March 31, 2019, amounted to ¥835,336,416.14, compared to ¥817,835,805.47 at the end of the previous year[26] - The company's total liabilities stood at ¥157,699,394.66, slightly up from ¥157,394,609.28 in the previous quarter[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,062[12] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[12] - The total equity attributable to shareholders reached ¥623,145,876.32, an increase from ¥610,837,403.90 at the end of 2018[33] Research and Development - Research and development expenses rose significantly by 109.58% to ¥1,718,105.72 from ¥819,771.55, attributed to payments made according to R&D progress[16] - Research and development expenses for Q1 2019 were ¥1,718,105.72, nearly double the ¥819,771.55 spent in Q1 2018, indicating a strong focus on innovation[35] Non-Recurring Gains and Losses - The company reported non-recurring gains of ¥1,497,347.05, which included government subsidies and investment management income[9] - The company reported a substantial increase in non-operating income, which surged by 4133.07% to ¥402,868.90 from ¥9,517.18, primarily due to government subsidies received[16] Inventory and Cash Management - The cash and cash equivalents decreased to ¥75,157,539.57 from ¥85,123,156.90, indicating a reduction in liquidity[25] - The company’s inventory increased to ¥45,008,378.78 from ¥39,902,963.79, suggesting a buildup in stock levels[25] - The company's cash and cash equivalents decreased to ¥60,004,324.06 from ¥73,544,910.18, a decline of about 18%[29] Other Financial Metrics - The company reported a gross profit margin of approximately 10% for Q1 2019, compared to 11% in the same quarter last year, reflecting increased costs[35] - The accounts receivable balance was ¥163,164,760.08, slightly down from ¥168,687,810.15, indicating improved collection efforts[29] Reporting Practices - The first quarter report was not audited, indicating that the figures may be subject to change upon final review[51] - The company has not applied new financial instrument standards or new revenue recognition standards, indicating stability in reporting practices[50]

Financial Performance - The company's operating revenue for 2018 was ¥489,447,811.58, representing a 29.90% increase compared to ¥376,791,557.72 in 2017[6]. - The net profit attributable to shareholders for 2018 was ¥64,681,884.51, a 47.95% increase from ¥43,718,975.56 in 2017[6]. - The net profit after deducting non-recurring gains and losses was ¥46,976,467.38, which is an 11.79% increase from ¥42,020,955.66 in 2017[6]. - The net cash flow from operating activities for 2018 was ¥46,846,106.88, up 64.67% from ¥28,449,113.42 in 2017[6]. - The total assets at the end of 2018 were ¥817,835,805.47, an 8.62% increase from ¥752,926,669.00 at the end of 2017[6]. - The net assets attributable to shareholders at the end of 2018 were ¥611,597,582.76, a 10.08% increase from ¥555,582,698.25 at the end of 2017[6]. - The total profit for the company in 2018 was 30.94 billion yuan, reflecting a 9.5% growth compared to the previous year[35]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-on-year growth of 15%[122]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 86,670,000 shares[5]. - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares, totaling RMB 8,667,000, which represents 13.40% of the net profit attributable to shareholders for 2018[100]. - The cash dividend policy is in compliance with the company's articles of association and shareholder resolutions, ensuring transparency and protection of shareholder rights[96]. Product Development and Market Strategy - The company has 43 products listed in the National Medical Insurance Directory, which includes 20 Class A and 23 Class B products[28]. - The company’s main product, Panlong Qipian, is composed of 29 traditional Chinese herbs and is effective for treating various conditions such as rheumatoid arthritis and muscle injuries[29]. - The introduction of products into the National Essential Medicines List (2018 version) is expected to positively impact the company's market expansion and sales capabilities[28]. - The company has developed unique products such as Kebi Reti tablets, which address a market gap in oral medications for certain diseases[30]. - The company’s proprietary product, the Compound Acetate Cotton Phenol Tablets, is used for treating endometriosis and uterine fibroids, showcasing its diverse therapeutic applications[31]. - The company’s sales strategy includes specialized academic promotion for major products and precise distribution management for others, optimizing marketing costs[33]. - The company is actively exploring new product markets and enhancing brand image to increase sales revenue[53]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on innovative drug development[116]. Research and Development - R&D investment is emphasized, with collaborations with universities and research institutions to enhance product offerings and market competitiveness[39]. - The company is currently working on several R&D projects, including the production technology for Celecoxib and the consistency evaluation of Ranitidine capsules[70]. - The company has synthesized three new derivatives of cotton phenol and obtained a U.S. patent (Patent No: 9975849B1) for one of them[71]. - The company is investing 100 million RMB in research and development for new technologies aimed at improving production processes[119]. - The company has restructured its research institute into the "Shaanxi Panlong Pharmaceutical Research Institute" to enhance its scientific research capabilities[173]. Market Expansion and Competitive Position - The company is positioned in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine and chemical preparations, contributing to its robust market presence[36]. - The marketing network covers 28 provinces, with over 300 pharmaceutical companies and sales to more than 3,000 hospitals nationwide[44]. - The company has established a comprehensive industry chain integrating "planting, research, production, supply, and sales," enhancing market competitiveness[48]. - The company is focusing on integrating resources for research and development, establishing the Panlong Pharmaceutical Research Institute to boost innovation[53]. - The company is actively pursuing market expansion, targeting an increase in distribution channels by 30% in the next fiscal year[126]. Corporate Governance and Compliance - The company is focused on complying with regulations and improving corporate governance to protect investors' rights[88]. - The company has committed to not transferring shares for 36 months from the date of stock issuance, ensuring stability in shareholding[102]. - The company is actively pursuing compliance with its commitments regarding share transfers and lock-up periods, ensuring shareholder confidence[103]. - The company has established a clear framework for managing shareholding and transfer policies to align with regulatory requirements[105]. - The company has implemented measures to ensure compliance with the China Securities Regulatory Commission's requirements regarding return measures[130]. Social Responsibility and Community Engagement - The company has been recognized as a "National Poverty Alleviation Leading Enterprise" and "Advanced Poverty Alleviation Enterprise" by the State Council and Shaanxi provincial government[159]. - The company has signed contracts for the cultivation of medicinal materials covering over 50,000 acres, benefiting more than 7,520 impoverished individuals[162]. - The company has donated 500,000 CNY to the Shaanxi Charity Association for poverty alleviation and education support[158]. - The company has provided 3.5 million CNY in educational support to impoverished students[161]. - The company is exploring new poverty alleviation models to effectively open up income channels for impoverished households[168]. Shareholding Structure - The total number of shares before the change was 86,670,000, with 75% being restricted shares[177]. - The largest shareholder, Xie Xiaolin, holds 37,171,000 restricted shares, which remain unchanged[181]. - The company had a lock-up release on November 16, 2018, with 27,829,000 shares released, representing 32.1% of the total share capital[189]. - The company’s board of directors and senior management collectively hold 43,260,000 shares, which is approximately 52.5% of the total share capital[195]. - The company has not engaged in any trust or asset management methods to control the company[189].

1 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 证券代码：002864 证券简称：盘龙药业 公告编号：2018-063 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)吴继文声明：保证季度报告中财务报表的真实、准确、完整。 2 陕西盘龙药业集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 819,029,870.69 | | 752,926,669.00 | 8.78% | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2018, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[14]. - The company aims to achieve a revenue growth target of 20% for the full year 2018[14]. - The gross margin for the first half of 2018 was reported at 45%, a slight decrease from 47% in the previous year[14]. - The company's operating revenue for the reporting period was ¥208,339,577.45, representing a 29.13% increase compared to ¥161,346,961.24 in the same period last year[20]. - The net profit attributable to shareholders was ¥29,999,006.58, reflecting a significant increase of 71.07% from ¥17,535,728.68 in the previous year[20]. - The basic earnings per share rose to ¥0.35, up 29.63% from ¥0.27 in the previous year[20]. - The total profit of CNY 35,161,267.20, which is an increase of 67.2% compared to CNY 21,025,823.45 in the previous year[147]. - The company achieved investment income of CNY 4,524,387.23, with no comparable figure from the previous year[147]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces by the end of 2018[14]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market share[14]. - The company has implemented a new procurement strategy to reduce costs by 5% across its supply chain[14]. - The sales strategy includes specialized academic promotion for key products and precise distribution management for other drugs, optimizing marketing costs[34][35]. - The company is actively exploring new product markets and enhancing its brand image to strengthen its market position[56]. - The company plans to establish a national trading market for Astragalus, integrating planting, storage, processing, and logistics[57]. Research and Development - Research and development expenses increased by 25% to RMB 30 million, focusing on new drug formulations and technologies[14]. - The company will continue to invest heavily in drug research and development to expand its product line, despite the inherent uncertainties[86]. - The company completed clinical verification for the product "Panlong Seven Tablets" with 137 cases enrolled, enhancing its market influence[57]. Inventory and Assets - Inventory increased by 50.02%, attributed to higher sales volume and routine maintenance of production facilities[40]. - The total assets at the end of the reporting period were ¥792,729,173.74, marking a 5.29% increase from ¥752,926,669.00 at the end of the previous year[20]. - Accounts receivable increased by 29.39% to ¥172,387,413.41, making up 21.75% of total assets, attributed to sales revenue growth[68]. - Inventory rose by 76.56% to ¥47,953,184.11, representing 6.05% of total assets, due to increased sales scale and routine maintenance[68]. Social Responsibility and Community Engagement - The company has established a partnership with Xichuan Village in Shaanxi Province and various towns in Huachi County, Gansu Province, focusing on targeted poverty alleviation efforts[112]. - A total of 320 individuals have been trained through 14 training sessions aimed at enhancing local agricultural practices and increasing income[112]. - The company has committed to purchasing all harvested medicinal materials from local farmers, ensuring a stable income source for them[112]. - The company emphasizes a dual approach to poverty alleviation, combining "blood transfusion" and "blood production" strategies to ensure sustainable development[114]. Financial Health and Stability - The company has not engaged in any significant non-raised fund investment projects during the reporting period[81]. - The overall financial health of the company appears stable, with a focus on maintaining equity levels[168]. - The company maintains a continuous operation capability for at least 12 months from the report date, with no significant issues affecting its operational capacity[176]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 22,538[124]. - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[124]. - The total number of shares is 86,670,000, with 75.00% being limited shares[122]. - The company did not distribute cash dividends or issue bonus shares during the reporting period[91]. Risks and Challenges - The company faces industry policy risks due to stringent regulations affecting the pharmaceutical sector, which may impact future development[85]. - The company is also exposed to drug price reduction risks, influenced by policy-driven price cuts and market competition[86]. - The company plans to enhance its quality management to mitigate product quality safety risks arising from new regulations[86].

Financial Performance - The company's revenue for Q1 2018 reached ¥94,246,673.75, representing a 41.57% increase compared to ¥66,572,071.94 in the same period last year[9] - Net profit attributable to shareholders was ¥9,613,067.73, up 39.52% from ¥6,890,112.93 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥8,215,885.68, reflecting a 24.47% increase from ¥6,600,454.01 in the previous year[9] - Basic and diluted earnings per share were both ¥0.1109, an increase of 4.62% from ¥0.1060 in the previous year[9] - The company expects net profit attributable to shareholders for the first half of 2018 to range from ¥1,800,000 to ¥2,200,000, representing a growth of 2.65% to 25.46% compared to the same period in 2017[23] Cash Flow and Assets - The net cash flow from operating activities was ¥3,697,480.38, showing a significant increase of 91.29% compared to ¥1,932,939.29 in the same quarter last year[9] - Total assets at the end of the reporting period were ¥767,819,109.91, a 1.98% increase from ¥752,926,669.00 at the end of the previous year[9] - Net assets attributable to shareholders amounted to ¥565,195,765.98, up 1.73% from ¥555,582,698.25 at the end of the last year[9] - The company's cash and cash equivalents decreased by 79.15% to ¥62,846,714.40 due to the purchase of wealth management products[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,892[13] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[13] Operating Performance - Operating revenue increased by 41.57% to ¥94,246,673.75, primarily driven by sales growth[17] - Operating costs rose by 46.11% to ¥29,899,966.47, in line with increased sales[17] - Net cash flow from operating activities improved by 91.29% to ¥3,697,480.38, attributed to higher operating revenue[17] Investment Strategy and Risk Management - The company has adopted a prudent investment strategy, focusing on low-risk wealth management products to enhance capital efficiency[18] - The financial department will continuously monitor investment products to mitigate risks affecting capital safety[20] Compliance and Commitments - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[22] - There were no violations regarding external guarantees during the reporting period[24] - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[25] Non-Operating Income - The company reported non-operating income of ¥1,864,832.29 from fair value changes of financial assets, contributing to its overall financial performance[10]